- Oklahoma Bureau of Narcotics Recruits SumTotal to Curb Drug Abuse
SumTotal® Systems (Nasdaq: SUMT), the largest provider of talent and learning solutions, announced that the Oklahoma Bureau of Narcotics and Dangerous Drugs (OBNDD) has chosen SumTotal’s software to build an online curriculum to stem the abuse of drugs, specifically methamphetamines. OBNDD will develop and deliver web-based courses with SumTotal’s learning and content management systems. - Newly Published Editorial in Expert Opinion on Investigational Drugs Says Statins May Be Good
A newly published editorial in Expert Opinion on Investigational Drugs has concluded that statins, the widely used cholesterol drugs, “probably strike at the heart of the sporadic Alzheimer’s disease-inducing mechanism” (Expert Opin. Investig. Drugs (Dec. 2006) 15(12):1479-1485). - Lipicard’s Platrol® – the Safest Anti-Platelet Drug – the Fastest to Market as Well!
Platrol® has demonstrated 40% more efficacy and negligible toxicity in limited clinical trials resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs. And Platrol®’s inherent sustained release property makes it even better as a long-term cardio-protective drug. - Aetna to Help Members Quit Tobacco with New Tobacco Cessation Program
As the American Cancer Society celebrates the 30th annual Great American Smokeout® this week, Aetna (NYSE:AET) today announced the availability of the new Aetna Quit Tobacco program. The Quit Tobacco program is a voluntary, one-year program that offers personal coaching and support by certified tobacco cessation specialists. - Genetic Engineering News Reports on Efforts to Foil Counterfeit Drugs
Biotech and pharmaceutical firms are becoming increasingly worried over the issue of counterfeit drugs, reports Genetic Engineering News (GEN) (www.genengnews.com). Their concerns are being fueled by higher threat levels, the value of the products involved, and the number of counterfeit drugs being produced, according to an article in the November 1 issue of GEN. - Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 to Be Presented at Upcoming ACR Meeting
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that posters regarding its product candidates, CRx-102 and CRx-139 will be presented at the American College of Rheumatology (ACR) meeting November 10-15, 2006 in Washington, DC. - AMRI Launches Interactive Drug Discovery Tool, ''AMRIDirect''
Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced the launch of AMRIDirect (www.amridirect.com), a searchable, online database of drug-like compounds for use in drug discovery. - ABMC Announces Expansion of Sales of Its Rapid Drug Screen® in Spain
American Bio Medica Corporation (NASDAQ: ABMC) has announced today that they have received an initial order of 80,000 units for its Rapid Drug Screen (RDS®) from Diagnosticos Rapidos De España of Sevilla, Spain, ABMC’s distributor in Spain since June 2004. The value of the order exceeds $400,000 (USD). - Revamping the U.S. Drug Safety System: Cleveland Clinic’s Steven Nissen
The Food and Drug Administration’s (FDA) approach to drug safety is headed for significant changes in the wake of several high-profile drug withdrawals, critiques of the advisory committee process, and pending legislation to revamp its review procedures. These changes will have a lasting impact on the companies that develop and market regulated drugs. - Medtronic Announces Positive Results for Endeavor RESOLUTE Drug-Eluting Coronary Stent System
Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, today presented positive preliminary results from the Medtronic RESOLUTE clinical trial, a first-in-man study evaluating the new Endeavor RESOLUTE zotarolimus-eluting stent system. Four-month angiographic and clinical results reinforce that zotarolimus continues to be a very potent drug in preventing restenosis, even in challenging patient populations. - Drugs Approved for the Treatment of Leukemia: a Historical Perspective
Research and Markets (http://www.researchandmarkets.com/reports/c43880) has announced the addition of “Hematological Cancers - A Therapeutic & Competitive Insight” to their offering. - Zacks Analyst Interview Highlights: Wal-Mart, Walgreen, CVS and Rite Aid.
Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Steven Ralston, who discusses Wal-Mart (NYSE: WMT), Walgreen (NYSE: WAG), CVS (NYSE: CVS) and Rite Aid (NYSE: RAD). - Winning FDA Approval for Combination Drugs
Preparing for an FDA Advisory Committee hearing is an intensely collaborative process that is magnified enormously when the application is for a combination product,” declared Michael J. Vivion, executive director, ECG, communication consultants to the healthcare industry. Dr. Vivion spoke on October 17 at the 2006 Annual Conference and Exhibition of the Regulatory Affairs Professionals Society (RAPS) held at the Baltimore Convention Center, October 15 – 18. - Gene Logic Enters into Agreement with Lilly to Discover New Development
Gene Logic Inc. (NASDAQ: GLGC) announced today that it has entered into a drug repositioning and development agreement with Eli Lilly and Company to seek alternative development paths for multiple Lilly drug candidates. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety. - WebAlert: MultiCell Technologies to Release CEO Interview to Discuss Progress in Business
MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on modulation of the immune system, will release an audio interview with Dr. Stephen Chang, President and Chief Executive Officer of MultiCell, on Monday, October 16, at 12 noon Eastern. - Financial Innovations Can Help Produce New Medicines Through Funding of Early-Stage Drug Development
Public and private funding in biomedical research has declined – a trend that could jeopardize efforts to find improved treatments for people with life-threatening illnesses.
A new report from the Milken Institute demonstrates that innovative financial tools can lower investor risk and increase the flow of capital to research. - CombinatoRx to Present at the 2006 BIO Investor Forum
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that Alexis Borisy, President & Chief Executive Officer, is scheduled to provide a corporate update at the upcoming BIO Investor Forum held at the Palace Hotel in San Francisco, CA on October 19, 2006 at 9:40am PT. - Drug Payment Methodology Task Force Established by the Academy of Managed Care Pharmacy
It was announced today that the Academy of Managed Care Pharmacy (AMCP) has initiated an assessment of current payment methodologies used by purchasers such as private health plans and the Medicare and Medicaid programs to pay for prescription drug products. - Understanding the Issues Relating to Chirality in Drug Research
Research and Markets (http://www.researchandmarkets.com/reports/c43175) has announced the addition of Chirality in Drug Research to their offering.
This practice-oriented handbook highlights all issues relating to chirality of pharmaceuticals, from challenges in the synthesis of these complex molecules to analytical techniques to aspects of pharmacology and drug development. It is highly useful for every medicinal chemist involved in small molecule drug development. - Auriga Files Key Patent on Advanced Drug-Delivery Method to Expand Company’s New Drug Development
Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced the filing of a new provisional patent application for colonic delivery of corticosteroids that further expands the Company’s proprietary technology portfolio. - PBMI Webcast Will Help Employers Actively Manage Specialty Drug Coverage
The steps employers should be taking to better manage specialty drug coverage will be discussed in a Webcast hosted by the Pharmacy Benefit Management Institute (PBMI) from 2:00 to 3:30 p.m. Eastern Daylight Time on October 11, 2006. Webcast registration is available at www.pbmi.com. - Alfacell Completes Non-Clinical Section of Rolling NDA for Lead Anticancer Drug ONCONASE®
Alfacell Corporation (NASDAQ: ACEL) today announced that the company has completed the non-clinical section of the rolling submission of a New Drug Application (NDA) in preparation for its submission to the U.S. Food and Drug Administration (FDA) for its lead anticancer compound, ONCONASE (ranpirnase). - Sierra Health Services Announces Continued Participation in Medicare Prescription Drug Program
Sierra Health Services, Inc. (NYSE:SIE) announced today that its wholly owned subsidiaries, Sierra Health and Life Insurance Company, Inc. (SHL) and Health Plan of Nevada, Inc. (HPN), have been selected by the Centers for Medicare & Medicaid Services (CMS) to participate for 2007 in the stand-alone prescription drug plan (PDP), Medicare Advantage HMO, Local and Regional PPO programs, and the Medicare Advantage Private Fee-For-Service (PFFS) program. - Landmark Five-Year Data on Gilead’s Anti-HIV Drug Viread® Presented at 8TH International Workshop
Gilead Sciences, Inc. (Nasdaq: GILD) today announced two presentations of long-term efficacy and safety data from Study 903E on the company’s leading once-daily anti-HIV medication, Viread® (tenofovir disoproxil fumarate). - Flu Shots Available at Walgreens Beginning Oct. 2
Walgreens will offer more than 6,000 in-store flu and pneumonia vaccination clinics during its annual program Oct. 2 through Nov. 17. No appointment is necessary for vaccinations. - Pandemic Risk Increases – Anti Virals Losing Effectiveness, According to Firestorm Solutions
Firestorm Solutions, LLC’s president, Jim Satterfield, jsatterfield@firestorm.com, cautioned today “In light of the World Health Organization (WHO) announcement that the two most prevalent anti-viral drugs are losing their effectiveness against the avian flu, pandemic response plans must be reviewed and updated.” - Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment
Greater antiretroviral suppression was maintained after 24 weeks of therapy with MK-0518i, an investigational oral HIV integrase inhibitor in combination with optimized background therapy (OBT) versus placebo plus OBT in HIV-infected patients who failed antiretroviral therapy (ART) and who were resistant to drugs in all three classes of oral antiretroviral drugs. - Harvard Researchers Recognize S.C. BlueCross Initiative to Make Prescription Comparisons Easier
Harvard Medical School’s Department of Health Care Policy has selected BlueCross BlueShield of South Carolina’s My Pharmacy ManagerSM† for honors this week. The program was chosen for its approach to helping consumers tackle the challenge of comparing prescription medicine costs. - Alcon's TRAVATAN(R) Z Solution Approved by FDA for Treatment of Glaucoma
Alcon, Inc. (NYSE:ACL) announced today that the U.S. Food and Drug Administration (FDA) has approved TRAVATAN(R) Z (travoprost ophthalmic solution) 0.004% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, who are intolerant of or insufficiently responsive to other intraocular pressure lowering medications. - DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), announced today that it has submitted in the Electronic Common Technical Document format a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") to market orBec(R) (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease ("GI GVHD") - PhytoMedical Announces Addition of Proven Industry Executive
PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) today announced the addition of James F. Lynch, PhD, MBA, President of Strategic Access, Inc., to its Scientific Advisory Board. - Calgenex Corporation Founded to Address Problem of Soft Tissue Calcification
Grant Carlson today announced the formation of Calgenex Corporation, a manufacturer and marketer of dietary supplements, topical over-the-counter (OTC) drugs, and personal care products specially formulated to combat the effects of soft tissue calcification and inflammation. Calgenex is one of the only companies in the world to address this pervasive yet often ignored medical condition. - Depomed to Present at the ThinkEquity Partners Growth Conference
Depomed, Inc. (NASDAQ:DEPO) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., will present on Wednesday, September 13, 2006 at 2:30 p.m. PT during the ThinkEquity Partners Growth Conference taking place in San Francisco. - Panacos Completes Pre-clinical Studies Indicating Bevirimat Is Non-Teratogenic
Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the completion of preclinical studies indicating that their lead drug candidate, bevirimat (PA-457), is non-teratogenic, meaning it did not cause fetal malformations in the models used in the studies.
|
Arts and Entertainment